Results of self-reported EHR COVID screenings among community oncology patients

Mohammad N. MS, Karhade M. MD PhD, Robert N. MD, Wu N. MD, Heller B. MD, Alwardt S. PhD, Moore L., and Smith H. PhD MPH
The US Oncology Network (USON), US Oncology Research, Ontada (a McKesson Corporation business)

Background

- On March 11, 2020, the World Health Organization declared the COVID-19 pandemic a global emergency
- COVID-19 risk assessments needed to reduce potential infection
- Within 3 weeks, *iKnowMed* EHR implemented a COVID-19 screening tool *(Figure 1)*
- Provider-facing dashboard created to monitor the impact of COVID-19 within the community oncology setting

Figure 1: *iKnowMed* EHR Screening Survey ©



Objectives

- Monitor COVID-19 symptoms, travel, exposure and infection rates among cancer patients within The US Oncology Network

Methods

- COVID-19 data collected from McKesson *iKnowMed* EHR on screenings performed from March 2020 thru October 2021
- Screening data merged with inclusion criteria, defined as cancer patients who are in-care and receiving active treatment within The US Oncology Network
- Survey responses correlated with provider-facing COVID-19 screening dashboard *(Figure 2)*
- Outcomes included rates of COVID-19–related symptoms, travel, exposure, and testing results (*Tables 1, 2*)

Figure 2: COVID-19 Dashboard* : McKesson Practice Insights©



*Practice and location names de-identified due to compliance and legal reasons

Results

Table 1: COVID-19 Result Waterfall

Feature	Volume	Percentage
Base population	156,591	-
COVID-19 Screening	67,095	43% of base
COVID-19 Test	12,842	19% of screened
+(pos) COVID-19 Result	652	5% of tested
+ COVID-19, w/Symptoms	184	28% of + COVID-19
+ COVID-19, w/Exposure	66	10% of + COVID-19
+ COVID-19, w/Travel	14	2% of + COVID-19

Results (continued)

- A total of 156,591 unique patients satisfied inclusion criteria
- 43% (n=67,095) had at least one COVID-19 screening record
- 67% of the study population was female (n=45,057)
- 58% of the study population was aged 60-79 years (n=39,126)
- A median of 5 (IQR-2, 13) COVID-19 screenings per patient were reported
- 19% (n=12,842) reported having been tested for COVID-19
- 5% of those tested (n=652) reported a positive result

Table 2: COVID-19 Symptoms, Travel and Exposure

Screening Response	Symptoms, N (%)	Travel, N (%)	Exposure, N (%)
No	59,562 (89%)	54,280 (81%)	61,234 (91%)
Yes	1,679 (3%)	519 (1%)	265 (0.4%)
Unknown	5,852 (9%)	12,294 (18%)	5,595 (8%)

Conclusions

- The COVID-19 screening tool provides a valuable method to monitor cancer patients during the pandemic
- The COVID-19 screening tool is suggestive of future research directions
- Opportunities to stratify data by stage of disease, metastatic indication, and other clinical variables offer future directions for analysis.

Limitations

- Responses collected from *iKnowMed* EHR are patient self-reported, including responses to COVID-19 test results
- COVID-19 testing was not necessarily performed within the US Oncology Network practices